Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK revises US Avandia label to include new restrictions on use
GSK announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines.
-
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet
GSK & HGS announced publication Benlysta in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet.
-
GSK results announcement for the fourth quarter
Strategic progress drives positive underlying sales growth, increasing pipeline potential and improved cash generation.
-
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD
GSK & THRX announced major milestones in two clinical development programmes focused on new treatments for patients with COPD.
-
GSK announces the sale of its entire shareholding in Quest Diagnostics
GSK announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (Quest).
-
Update on Pandemrix™ and interim Finnish report on narcolepsy
GSK is aware of today's interim report by the Finnish National narcolepsy committee on their investigation into reported cases in Finland.
-
GSK and Actelion discontinue clinical development of almorexant
GSK & ATLN announced the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued.
-
GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication
GSK received a Complete Response letter from the FDA for the sNDA for Avodart for reducing the risk of prostate cancer in men.
-
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma
GSK announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation.
-
Regulatory update - GSK and Valeant receive positive opinion in Europe from the CHMP for Trobalt (retigabine)
GSK & VRX announced EMA's CHMP has issued a positive opinion, recommending marketing authorisation for Trobalt, treatment of seizures.
-
GSK and Prosensa announce start of Phase III study of investigational Duchenne Muscular Dystrophy medication
GSK and Prosensa announced - first patient has commenced treatment in the Phase III study investigating GSK2402968 in ambulant boys with DMD
-
GlaxoSmithKline commences Phase III study of intravenous zanamivir for hospitalised patients with influenza
GSK announced, patient has received treatment in Phase III study of hospitalised patients with influenza comparing zanamivir & oseltamivir
-
GlaxoSmithKline announces Q4 2010 legal charge
GSK announces that it expects to record a legal charge for the fourth quarter of 2010 of £2.2 billion ($3.4 billion) after tax £1.8 billion.
-
GlaxoSmithKline and ChemoCentryx announce initiation of Phase III study of GSK’786, formerly Traficet-EN™, for the treatment of Crohn’s disease
GSK & ChemoCentryx announced, first patient with Crohn's disease has initiated treatment in study comparing Traficet-EN, to placebo.
-
GlaxoSmithKline and DENTSPLY International sign global agreement to create a portfolio of co-branded professional oral care products
GlaxoSmithKline and DENTSPLY International, announced an agreement to create a portfolio of co-branded oral care products.
-
GSK responds to 60 Minutes
GSK issued response regarding a 60' program on Jan 2 that focused on a manufacturing facility in Puerto Rico, formerly owned by the company.
-
GlaxoSmithKline and Theravance commence MABA Phase IIb COPD study
GSK & THRX announced, first patient has started treatment with GSK961081 in a Phase IIb study to evaluate efficacy in patients with COPD.
-
GlaxoSmithKline and Impax Pharmaceuticals enter global agreement to develop and commercialise a late stage compound for Parkinson’s Disease
GSK & Impax announced, agreement for the development of IPX066 outside the US & Taiwan, product for the treatment of PD in Phase III trials.
-
Andrew Witty appointed Lead Non-Executive Board Member for the Department for Business, Innovation and Skills (BIS)
UK Gov announced, Andrew Witty appointed as the Lead Non-Executive Board Member for the Department for Business, Innovation and Skills.
-
GSK to strengthen Nutritional Healthcare business with acquisition of Maxinutrition
GSK entered into an agreement for acquisition of Maxinutrition protein-enhanced functional nutrition manufacturer from Darwin Private Equity
